Iman I Salama

Prof. Iman I Salama


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in World Journal of Hepatology
Verified
Journal Article
Open access
ISIman I Salama
Iman I Salama
SSSamia M Sami
Samia M Sami
ZSZeinab Nabil Ahmed Said
Zeinab Nabil Ahmed Said
MEManal H El-Sayed
Manal H El-Sayed
LELobna A El Etreby
Lobna A El Etreby
AMAmmal Mokhtar Metwally
Ammal Mokhtar Metwally
To assess the effectiveness of hepatitis B virus (HBV) vaccination program among fully vaccinated children. A national community based cross-sectional study was carried out in 6 governorates representing Egypt. A total of 3600 children aged from 9 mo to 16 years who were fully vaccinated with HBV vaccine during infancy were recruited. Face to face interviews were carried out and sera were evaluated for hepatitis B surface antigen (HBsAg), anti-HBV core antibodies (total) and quantitative detection of hepatitis B surface antibody using enzyme linked immunoassays techniques. Samples positive to HBsAg/anti-HBV core antibodies were subjected to quantitative HBV-DNA detection by real time polymerase chain reaction with 3.8 IU/L detection limit. Sero-protection was detected among 2059 children (57.2%) with geometric mean titers 75.4 ± 3.6 IU/L compared to 3.1 ± 2.1 IU/L among non-seroprotected children. Multivariate logistic analysis revealed that older age and female gender were the significant predicting variables for having non sero-protective level, with adjusted odds ratio 3.3, 9.1 and 14.2 among children aged 5 to < 10, 10 to < 15 and ≥ 15 years respectively compared to those < 5 years and 1.1 among girls compared to boys with P < 0.01. HBsAg was positive in 0.11% and breakthrough infection was 0.36% and 0.39% depending on positivity of anti-HBc and DNA detection respectively. The prevalence of HBV infection was significantly higher among children aged ≥ 7 years (0.59%) compared to 0.07% among younger children with odds ratio equal to 8.4 (95%CI: 1.1-64.2) and P < 0.01.The prevalence was higher among girls (0.48%) than boys (0.29%) with P > 0.05. The Egyptian compulsory HBV vaccination program provides adequate protection. Occult HBV infection exists among apparently healthy vaccinated children. Adherence to infection control measures is mandatory.

1 January 2013 in World Journal of Hepatology
Verified
Journal Article
Open access
ZSZeinab Nabil Ahmed Said
Zeinab Nabil Ahmed Said
MSManal H El Sayed
Manal H El Sayed
ISIman I Salama
Iman I Salama
EAEnas K Aboel-Magd
Enas K Aboel-Magd
MMMagda H Mahmoud
Magda H Mahmoud
GEGamal E Esmat
Gamal E Esmat
AIM: To identify blood donors with occult hepatitis B virus (HBV) infection (OBI) to promote safe blood donation. METHODS: Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) and human immunodeficiency virus Ab. They were subjected to the detection of alanine aminotransferase (ALT) and aspartate transaminase (AST) and screening for anti-HBV core antibodies (total) by two different techniques; [Monoliza antibodies to hepatitis B core (Anti-HBc) Plus-Bio-Rad] and (ARC-HBc total-ABBOT). Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface (anti-HBs) (ETI-AB-AUK-3, Dia Sorin-Italy). Serum anti-HBs titers > 10 IU/L was considered positive. Quantitative HBV DNA by real time polymerase chain reaction (PCR) (QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 IU/L. Also, 265 recipients were included, 34 of whom were followed up for 3-6 mo. Recipients were investigated for ALT and AST, HBV serological markers: HBsAg (ETI-MAK-4, Dia Sorin-Italy), anti-HBc, quantitative detection of anti-HBs and HBV-DNA. RESULTS: 525/3167 (16.6%) of blood units were positive for total anti-HBc, 64% of those were anti-HBs positive. Confirmation by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples, where 451 (90.6%) confirmed positive. Reactivity for anti-HBc was considered confirmed only if two positive results were obtained for each sample, giving an overall prevalence of 451/3167 (14.2%) for total anti-HBc. HBV DNA was quantified by real time PCR in 52/303 (17.2%) of anti-HBc positive blood donors (viral load range: 5 to 3.5 x 105 IU/mL) with a median of 200 IU/mL (mean: 1.8 x 104± 5.1 x 104 IU/mL). Anti-HBc was the only marker in 68.6% of donors. Univariate and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity among blood donors showed that age above thirty and marriage were the most significant risk factors for prediction of anti-HBc positivity with AOR 1.8 (1.4-2.4) and 1.4 (1.0-1.9) respectively. Other risk factors as gender, history of blood transfusion, diabetes mellitus, frequent injections, tattooing, previous surgery, hospitalization, Bilharziasis or positive family history of HBV or HCV infections were not found to be associated with positive anti-HBc antibodies. Among anti-HBc positive blood donors, age below thirty was the most significant risk factor for prediction of HBV-DNA positivity with AOR 3.8 (1.8-7.9). According to HBV-DNA concentration, positive samples were divided in two groups; group one with HBV-DNA ≥ 200 IU/mL (n = 27) and group two with HBV-DNA < 200 IU/mL (n = 26). No significant difference was detected between both groups as regards mean age, gender, liver enzymes or HBV markers. Serological profiles of all followed up blood recipients showed that, all were negative for the studied HBV markers. Also, HBV DNA was not detected among studied recipients, none developed post-transfusion hepatitis (PTH) and the clinical outcome was good. CONCLUSION: OBI is prevalent among blood donors. Nucleic acid amplification/HBV anti core screening should be considered for high risk recipients to eliminate risk of unsafe blood donation.

1 December 2004 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MEManal H El-Sayed
Manal H El-Sayed
AEAlaa El-Haddad
Alaa El-Haddad
OFOmar A Fahmy
Omar A Fahmy
ISIman I Salama
Iman I Salama
HMHossam K Mahmoud
Hossam K Mahmoud
Liver disease is an important cause of morbidity and mortality among recipients of bone-marrow transplantation (BMT). The aim of this retrospective study was to determine the incidence, risk factors and clinical evolution of liver disease following allogeneic BMT. A total of 103 patients (mean age 22.8 years (SD 10.9); 31.1% aged < 18 years; 66% males) transplanted in a single institution were enrolled. Data on donors and recipients were collected, including hematological disease, alanine transaminase, alkaline phosphatase, bilirubin, hepatitis B virus (HBV) and hepatitis C virus (HCV) markers (including HBV-DNA and HCV-RNA). Fifty six of 103 patients died, with liver disease the main cause of death (27 of 56, 48%). Overall the incidence of liver failure attributed to hepatic graft-versus-host-disease (GVHD) was 22.3% (23 of 103; 74% HBV/HCV infected) and veno-occlusive disease (VOD) was 9.7% (10 of 103; 80% HBV/HCV infected). Fourteen patients had hepatitis reactivations (four hepatic GVHD and three VOD). Donors’ HCV-RNA status and serum bilirubin above 2 mg/dl were predictive of hepatic GVHD [adjusted odds ratio (AOR) 11.1, 95% confidence interval (CI) 0.99–33.12; AOR 3.93, 95% CI 1.09–14.62; P < 0.05, respectively] and an abnormal alkaline phosphatase could predict severe liver disease (AOR 2.78, 95% CI 1.01–7.54; P < 0.05). Development of severe liver disease (hepatic GVHD or VOD) was a significant predictor of mortality (AOR 4.57, 95% CI 1.09–20.32; P < 0.05) with a low probability of survival (19.3%, SD 7.9%) compared with those without liver disease (52.1%, SD 7.6%; log-rank P = 0.0003). Hepatic GVHD is a common complication following BMT and an important cause of liver-related mortality. The high prevalence of HCV and HBV may have contributed to the outcome of hepatic GVHD and VOD. Therefore, antiviral therapy should be considered early to prevent relentless progression of liver disease.

10 March 2009 in Liver International
Verified
Journal Article
Closed access
ZSZeinab Nabil Ahmed Said
Zeinab Nabil Ahmed Said
MEManal H. El‐Sayed
Manal H. El‐Sayed
IEIman A. El‐Bishbishi
Iman A. El‐Bishbishi
DEDaad F. El‐Fouhil
Daad F. El‐Fouhil
SASoad E. Abdel‐Rheem
Soad E. Abdel‐Rheem
ISIman I Salama
Iman I Salama

27 June 2022 in World Journal of Hepatology
Verified
Journal Article
Open access
ISIman I Salama
Iman I Salama
HRHala M Raslan
Hala M Raslan
GAGhada A Abdel-Latif
Ghada A Abdel-Latif
SSSomaia I Salama
Somaia I Salama
SSSamia M Sami
Samia M Sami
WFWalaa A Fouad
Walaa A Fouad
Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection

1 November 2007 in Eastern Mediterranean Health Journal
Verified
Journal Article
Closed access
ISIman I Salama
Iman I Salama
SSS.M. Samy
S.M. Samy
FSF.A. Shaaban
F.A. Shaaban
AHA.I. Hassanin
A.I. Hassanin
LIL.A. Abou Ismail
L.A. Abou Ismail
To determine seroprevalence of anti-hepatitis A virus (HAV) antibodies and potential risk factors for and age of contracting symptomatic hepatitis A infection among children of different socioeconomic status (SES) in Cairo, we carried out a cross-sectional study on 426 children aged 3-18 years from low SES areas and 142 from high SES areas. Seroprevalence was significantly higher with age. Seropositivity to anti-HAV antibodies was significantly higher among children of low and very low SES, 90%, compared to children of high SES, 50%. Water supply and sewage disposal were the most significant risk factors for HAV seropositivity in children of low SES. Children of high SES were more likely to be vulnerable to infection in adolescence than those of low SES.